Abstracts tagged "innate immunity"

Abstract Number: LB22 • ACR Convergence 2025
Early Evidence of Proof-of-Concept of an Albumin-DNASE1L3 Fusion Protein (NTR-441) for the Rapid Enzymatic Inactivation of NETs in SLE with DNASE1L3-Deficiency
Andreas Reiff¹, Tadej Avcin², Bernd Jilma³, Peter Korosec⁴, Matthias Weiss-Tessbach³, Christian Schoergenhofer³, Masa Bizjak⁵, Barbara Jenko Bizjan⁶, Barbara Cugalj Kern⁵, Kim Simpfendorfer⁷, Christian Lood⁸, Tyler Artner⁹, Angelene Prasanna¹, Ken Olivier¹, Ghazaleh Gouya¹, Ralph Lambalot⁹, Abdul Hakkim¹ and Tobias Fuchs¹, ¹Neutrolis, Cambridge, Massachusetts, ²University Medical Centre Ljubljana, Ljubljana, Slovenia, ³Medical University of Vienna, Vienna, Austria, ⁴University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia, ⁵University Medical Center Ljubljana, Ljubljana, Slovenia, ⁶University of Ljubljana, Ljubljana, Slovenia, ⁷Feinstein Institutes for Medical Research, Manhasset, New York, ⁸University of Washington, Seattle, Washington, ⁹Neutrolis, Cambridge
Background/Purpose: Excessive formation and impaired clearance of Neutrophil Extracellular Traps (NETs) have been linked to autoimmune and inflammatory diseases, notably systemic lupus erythematosus (SLE). DNASE1-like…
Abstract Number: 1602 • ACR Convergence 2025
Biomarkers of Innate Immune Activation to Identify Non-Response to Rituximab in Granulomatosis with Polyangiitis
Irene Carrión-Barberà¹, Jorge A. Gonzalez-Chapa², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Kenneth Warrington¹², Peter Merkel⁷ and Christian Lood², ¹Department of Rheumatology. Hospital del Mar, Barcelona, Spain, ²University of Washington, Division of Rheumatology, Seattle, ³University of South Florida, Tampa, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN
Background/Purpose: Innate immune activation plays a key role in granulomatosis with polyangiitis (GPA), contributing to vascular inflammation via neutrophil extracellular traps, immune complexation (IC), and…
Abstract Number: 0920 • ACR Convergence 2025
Functional Characterization of NEMO-NDAS Causing Variants in Patients’ PBMCs and in Wildtype and Mutant U937 Cells
Elizabeth Morgan¹, Bin Lin², Sara alehashemi¹, Adriana de Jesus¹, Keith Kauffman³, Christopher Friend¹, Farzana Bhuyan¹, Kader Gedik¹, Kat Uss¹, Lauren Krausfeldt⁴, Jason Brenchley⁵, Zoran Gucev⁶, Kathryn Cook⁷, Vafa Mammadova⁸, Gulnara Nasrullayeva⁸, Mariana Correia Marques⁹, Abigail Bosk¹⁰, Brian Nolan¹¹, Scott Canna¹², Maude Tusseau¹³, Andrea Bohrer¹⁴, Katrin Mayer-Barber¹⁵, Timothy Moran¹⁶, Andrew Oler⁴, Daniel Barber³ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Diseases Section (TADS), Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, NIH, Bethesda, MD, ²NIH, Bethesda, MD, ³T-Lymphocyte Biology Section, Laboratory of Parasitic Diseases, NIAID, NIH, Bethesda, MD, ⁴Bioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, NIAID, NIH, Bethesda, MD, ⁵Barrier Immunity Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, ⁶University Children's Hospital, Medical Faculty Skopje, Skopje, Macedonia, ⁷Akron Children’s Hospital, Akron, OH, ⁸Azerbaijan Medical University, Baku, Azerbaijan, ⁹Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁰Children’s National Hospital, Washington DC, ¹¹Lurie Children’s Hospital, Chicago, ¹²Children's Hospital of Philadelphia, Philadelphia, PA, ¹³Hôpital Femme-Mère-Enfant, Bron, France, ¹⁴Inflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, NIH, Bethesda, MD, ¹⁵Inflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology (LCIM), Bethesda, MD, ¹⁶University of North Carolina School of Medicine, Chapel Hill, NC
Background/Purpose: NEMO-deleted 5 autoinflammatory syndrome (NEMO-NDAS) is an inflammatory disease caused by mosaic splice-site variants that lead to exon 5 skipping in IKBKG, encoding NEMO.…
Abstract Number: 1535 • ACR Convergence 2025
INB-619 – A Novel Gamma-Delta (γδ) T cell Engager to Target B cells in Autoimmune Diseases
Lei Ding, Yanjie Li, Mariska ter Haak, Sadhak Sengupta, Kate Rochlin and Lawrence Lamb, IN⁸bio, Inc., New York, NY
Background/Purpose: T cell engagers (TCEs) redirect T cells to bind target cells by linking T cells with target-associated antigens expressed on cells responsible for disease…
Abstract Number: 0910 • ACR Convergence 2025
Development of Four Distinct Human IgG4-Producing Mouse Models Recapitulating IgG4-Related Disease
MIN GANG KIM¹, JINA YEO², HEA RIM KANG³, JAE HYUN MOON³, Seon Uk Kim⁴, SeoYoon Ban⁵, MI HYEON KIM⁶ and Eun Young Lee⁷, ¹Seoul National University College of Medicine, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea, ³Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, ⁴Seoul National University, Jongno-gu, Seoul, Republic of Korea, ⁵Department of Cancer biology, Graduate School of College of Medicine, Seoul National University, Korea, Seoul, Republic of Korea, ⁶Hallym university dongtan sacred heart hospital, Seocho-gu, Seoul, Republic of Korea, ⁷Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: IgG4-related disease (IgG4RD) is an immune-mediated fibroinflammatory condition characterized by multi-organ involvement, elevated serum IgG4, and IgG4-positive plasma cell infiltrates that form tumor-like lesions…
Abstract Number: 1145 • ACR Convergence 2025
Numerically Reduced but MSU Crystal-Activated NK Cells Promote Osteoclastogenesis in Gout
Ki-Jeong Park¹, Young-Nan Cho², Hye-Mi Jin², Hye-Min Jeong², Sung-Eun Choi³, Ji-Hyoun Kang¹, Dong-Jin Park¹, Tae-jong Kim⁴, Shin-Seok Lee⁵ and Yong-Wook Park⁶, ¹Chonnam National University Hospital, Gwangju, Republic of Korea, ²Chonnam National University Medical School, Gwangju, Republic of Korea, ³Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea, ⁴Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwang-Ju, South Korea, ⁵Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ⁶Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea
Background/Purpose: Gout is an inflammatory arthritis characterized by acute attacks, tophi formation, and bone destruction triggered by inflammatory responses to monosodium urate (MSU) crystals. Natural…
Abstract Number: 0571 • ACR Convergence 2025
Single-cell RNA Sequencing Highlights the Role of Innate Immunity in Identifying Candidates for Early Biologics Treatment in Axial Spondyloarthritis
Jaejoon Lee¹, A-Hyun Cho², Yu Jin Kim², Seulkee Lee³, Seonyoung Kang⁴, Hyungjin Kim⁵, Hoon-Suk Cha¹ and Hong-Hee Won², ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ²Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea, ³Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, Republic of Korea, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Biologics have transformed the management of axial spondyloarthritis (axSpA). Currently, it is challenging to identify patients who would benefit from early biologics, resulting in…
Abstract Number: 1131 • ACR Convergence 2025
Variant Drives Tophus Formation through Dual Mechanisms: Extracellular Aggregation andvImpaired Macrophage Phagocytic Clearance
Yuqi wang¹, Lingjiang Zhu¹, Jinshuo Han², Junbin Qian³, Martin Herrmann⁴, Jing Xue¹ and Lei Liu¹, ¹The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China (People's Republic), ²Zhejiang University, School of Medicine, Hangzhou, China (People's Republic), ³Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China (People's Republic), ⁴University Hospital Erlangen, Erlangen, Germany
Background/Purpose: While aggregated neutrophil extracellular traps (aggNETs) constitute the primary structural component of tophi, the susceptible population for tophaceous gout remains poorly characterized. We investigated…
Abstract Number: 0723 • ACR Convergence 2025
Neutrophil and Eosinophil Extracellular Traps in Eosinophilic Granulomatosis with Polyangiitis: Phenotype-based Characterization and Response to Mepolizumab
Michele Moretti¹, Francesco Ferro², Francesco Pisani³, Elisa Ferrigno³, Gaetano La Rocca⁴, Federica Di Cianni⁵, Rosaria Talarico⁶, Marta Mosca⁷, Chiara Baldini⁷ and Ilaria Puxeddu³, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³University of Pisa, Pisa, Italy, ⁴University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ⁵Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁶Azienda Ospedaliero Universitaria Pisana, Pisa, Pisa, Italy, ⁷University of Pisa, Pisa, Pisa, Italy
Background/Purpose: EGPA variably presents eosinophil (EOS)-related features and vasculitic manifestations. Recent introduction of mepolizumab (MEP) has revolutionized the treatment of EOS manifestations of EGPA. However,…
Abstract Number: 1120 • ACR Convergence 2025
Synergistic Effects of IL-17F and IL-17A on Neutrophil Chemotaxis: Increased Risk of Candidiasis with Dual Blockade of IL-17A and IL17-F
Siba Raychaudhuri¹, Disha Chakraborty², Christine Abria² and Smriti K Raychaudhuri³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²Sacramento VA Medical Center, Mather, CA, ³Sacramento VA Medical Center, Davis, CA
Background/Purpose: IL-17 is primarily secreted by Th17 cells. The IL-17 family has 6 related cytokines (IL-17A to IL17F); IL-17A and IL-17F, being key proinflammatory mediators.…
Abstract Number: 0518 • ACR Convergence 2025
Deregulation of PSGL-1, HLA-DR and IFNα expression in peripheral innate immune cells of primary Sjögren Syndrome patients
Santos Castañeda¹, Alejandra Ramos-Manzano², Ines Sanchez-Abad³, Miren Uriarte-Ecenarro⁴, M. Paula Alvarez-Hernandez⁴, Esther San-Antonio⁴, Esther Vicente-Rabaneda⁵ and Ana Urzainqui⁴, ¹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ²Hospital Unversitario de la Princesa, Madrid, Madrid, Spain, ³Hospitla de la Princesa, Madrid, Spain, ⁴Hospital de la Princesa, Madrid, Madrid, Spain, ⁵Hospital Universitario de La Princesa, Madrid, Spain
Background/Purpose: Primary Sjögren's Syndrome (pSS) is an autoimmune disease characterized by lymphocytic infiltration of exocrine glands and systemic manifestations including cutaneous and renal involvement. Phagocytes--monocytes,…
Abstract Number: 2585 • ACR Convergence 2025
The effect of prophylactic colchicine use on gene expression in gout
Austin Wheeler¹, Guanqi Lu², Ana Vazquez³, Jeffrey Edberg⁴, Angelo Gaffo⁵, Tate Johnson¹, Michael Duryee¹, James O'Dell¹, Jeff Newcomb¹, Michael Pillinger⁶, Robert Terkeltaub⁷, Ryan Ferguson⁸, Mary Brophy⁸, Tuhina Neogi⁹, Bryant England¹, Ted Mikuls¹, Tony Merriman¹⁰ and Richard Reynolds⁴, ¹University of Nebraska Medical Center, Omaha, NE, ²Michigan State University, East Lansing, MI, ³Michigan State University, Miami, FL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ⁶New York University Grossman School of Medicine, New York,, NY, ⁷Retired, San Diego, CA, ⁸VA Cooperative Studies Program Coordinating Center, Boston, MA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Colchicine is recommended for the treatment and prophylaxis of gout flares and approved for secondary prevention of ischemic cardiovascular disease (CVD). While its primary…
Abstract Number: 1094 • ACR Convergence 2025
Changes in NK cells and TH cell phenotype in Rheumatoid Arthritis patients treated with janus kinase inhibitors: implications for adverse effects
Carmen Lasa Teja¹, Juan José Fernández-Cabero², Alejandra Comins-Boo³, David San Segundo³, Virginia Portilla González⁴, Montserrat Santos-Gomez⁵, José Luis Martín-Varillas⁶, Marcos López-Hoyos³ and Ricardo Blanco⁷, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ²Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Cantabria, Spain, ³Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, ⁵Division of Immunology, Hospital Sierrallana. Santander , Spain, Santander, Spain, ⁶Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, ⁷Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Janus kinase inhibitors (JAKi) are effective in rheumatoid arthritis (RA); however, concerns regarding safety, particularly the risk of infections and malignancies, have been raised.…
Abstract Number: 0514 • ACR Convergence 2025
Transitional Monocytes and Innate T Cell Populations Help Distinguish Ro Seropositive vs Ro Seronegative Sjögren’s Disease Using Whole Blood Immunophenotyping
Nicholas Bauer¹, Rufei Lu¹, Carla Guthridge¹, Tayte Stephens², Benjamin Jones³, Wade DeJager⁴, Susan Macwana¹, Caroline Shiboski⁵, Alan Baer⁶, Christopher Lessard¹, Astrid Rasmussen¹, Stephen Shiboski⁵, Judith James¹, Linda F. Thompson¹, Blake M. Warner⁷, A. Darise Farris¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Science Center, Oklahoma City, OK, ³Oklahoma State University, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵University of California San Francisco, San Francisco, CA, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷National Institutes of Health, Bethesda, MD
Background/Purpose: Blood immunophenotyping reveals systemic immune alterations and therapeutically actionable molecular endotypes in Sjögren’s Disease (SjD). Reported changes include reduced memory B cells, plasmacytoid dendritic…
Abstract Number: 2582 • ACR Convergence 2025
Inflammatory Cell Death and Impaired Efferocytosis Drive Monocyte and Macrophage Dysfunction in VEXAS Syndrome.
Paul Breillat¹, Samuel Magaziner², Stéphane Camus³, Lea Dionet⁴, Quentin Delcros⁵, Federica Pallotti⁶, Kevin Chevalier⁵, Margot Poux⁷, Olivia Lenoir⁸, Pierre-Louis Tharaux⁵, Olivier Kosmider⁹, David Beck¹⁰ and Benjamin Terrier¹¹, ¹INSERM, PARIS ¹⁷, Ile-de-France, France, ²Center for Human Genetics and Genomics, NYU Grossman School of Medicine, New York, NY, USA., New York, NY, ³Université de Paris, INSERM UMR⁹⁷⁰, Paris Cardiovascular Research Center, Paris, France., PARIS, France, ⁴INSERM, Paris, France, ⁵Paris Cardiovascular Research Center, Université Paris Cité, INSERM U⁹⁷⁰, Paris, France, PARIS, France, ⁶Internal Medicine and Clinical Immunology, Rennes, France, ⁷Université de Paris, PARIS ⁰⁴EME, France, ⁸Paris Cardiovascular Research Center, Université Paris Cité, INSERM U⁹⁷⁰, Paris, France, PARIS, Ile-de-France, France, ⁹AP-HP, Hopital Cochin, Institut Cochin, CNRS UMR⁸¹⁰⁴, INSERM U¹⁰¹⁶ Université Paris Cité Paris France., PARIS, France, ¹⁰Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, ¹¹Cochin Hospital, Paris, France
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a life-threatening systemic disorder characterized by inflammation and increased risk of opportunistic infections. VEXAS results from…

1
2
3
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].